Baodong Sun

Professor of Pediatrics

Pediatrics, Medical Genetics

baodong.sun@duke.edu

https://orcid.org/0000-0002-2191-0025

Box 103856 Med Ctr, Durham, NC 27710

905 S. LaSalle Street, GSRB1 Room 4024, Durham, NC 27710

More About This Person

At a Glance

Credentials
1. Education

Academic Experience
1. Current Duke Appointments & Affiliations
2. Previous Duke Appointments & Affiliations

Global Scholarship

Keywords

Research

Scholarly Works

Teaching & Mentoring

Recognition

Professional Activities

Scholarly Works - Conferences

AAV Gene Therapy with a Bacterial Glycogen Debranching Enzyme in a Dog Model of GSD IIIa

Conference MOLECULAR THERAPY · April 28, 2025 Link to item Cite

SEVERE PROGRESSION OF LIVER DISEASE IN AN AGING PHKG2^-/- MOUSE MODEL RECAPITULATES GSD IX G2 PATIENT PHENOTYPE

Conference MOLECULAR GENETICS AND METABOLISM · April 2022 Link to item Cite

Liver Directed AAV Gene Therapy Reverses Progression of Glycogen Storage Disease Type IX γ2 in Mice

Conference MOLECULAR THERAPY · April 2022 Link to item Cite

AAV Gene Therapy Effectively Transduces the Central Nervous System and Prevents Polyglucosan Body Formation in Adult Polyglucosan Body Disease Mice

Conference MOLECULAR THERAPY · 2022 Cite

Characterization of Liver Pathology in a Novel GSD IX y2 Mouse Model

Conference MOLECULAR THERAPY · April 27, 2021 Link to item Cite

Depletion of Pre-Existing Anti-AAV Neutralizing Antibodies by a Combination Immunosuppressive Treatment with Bortezomib and CD20 mAb Allows Successful Vector Re-Administration in Mice

Conference MOLECULAR THERAPY · April 27, 2021 Link to item Cite

AAV-Mediated Gene Therapy Using a Novel Dual Promoter Prevents Pullulanase-Induced Cytotoxic T Lymphocyte Response and Corrects Major Affected Tissues in GSD IIIa Mice

Conference MOLECULAR THERAPY · April 27, 2021 Link to item Cite

Immunosuppression with bortezomib and anti-CD20 mAb is effective in reducing neutralizing antibodies to allow repeated AAV administration in mice

Conference Molecular Genetics and Metabolism · February 2021 Full text Cite

Engineering α-glucosidase to improve protein stability and cellular uptake for the potential treatment of Pompe disease

Conference Molecular Genetics and Metabolism · February 2021 Full text Cite

A Combination Immunosuppression Treatment with Bortezomib and an Anti-CD20 mAb Enables Successful Re-Administration of AAV8 Vector in Mice

Conference MOLECULAR THERAPY · April 28, 2020 Link to item Cite

Transgene Immunogenicity Has Significant Effects on Gene Therapy in a Mouse Model of Adult Polyglucosan Body Disease

Conference MOLECULAR THERAPY · April 28, 2020 Link to item Cite

AAV-Mediated Gene Therapy for Glycogen Storage Disease Type III Using a Bacterial Glycogen Debranching Enzyme

Conference MOLECULAR THERAPY · April 28, 2020 Link to item Cite

COMPARATIVE LIVER PATHOLOGY IN GLYCOGEN STORAGE DISEASE TYPE IIIA

Conference MOLECULAR GENETICS AND METABOLISM · July 1, 2019 Link to item Cite

Correction of Glycogen Storage Disease Type III with an AAV Vector Encoding a Bacterial Glycogen Debranching Enzyme

Conference MOLECULAR THERAPY · April 22, 2019 Link to item Cite

COMPARATIVE LIVER PATHOLOGY IN GLYCOGEN STORAGE DISEASE TYPE IIIA

Conference MOLECULAR GENETICS AND METABOLISM · March 1, 2019 Link to item Cite

A Single Intravenous Injection of an AAV-PHP. B Vector Encoding Human Acid alpha-Glucosidase Corrects Both Muscle and Brain Defects in Murine Pompe Disease

Conference MOLECULAR THERAPY · May 1, 2018 Link to item Cite

Immunomodulation to enzyme replacement therapy with tolerogenic nanoparticles containing rapamycin in a murine model of Pompe disease

Conference Molecular Genetics and Metabolism · January 2017 Full text Cite

New perspectives for ERT in Pompe disease: Extending the action of the enzyme to cytosolic targets

Conference Molecular Genetics and Metabolism · February 2016 Full text Cite

Pathogenesis of Growth Failure in Murine and Canine Glycogen Storage Disease-Ia and Partial Reversal of Growth Failure Using Adeno-Associated Viral Vector Therapy

Conference MOLECULAR THERAPY · June 1, 2013 Link to item Cite

CHARACTERIZATION OF LIVER AND MUSCLE PHENOTYPES IN A CANINE MODEL OF GLYCOGEN STORAGE DISEASE TYPE IIIA

Conference JOURNAL OF INHERITED METABOLIC DISEASE · September 1, 2012 Link to item Cite

CARDIAC PATHOLOGY AND CLINICAL FINDINGS COMPARISON IN PATIENTS AND DOGS WITH GLYCOGEN STORAGE DISEASE TYPE III

Conference JOURNAL OF INHERITED METABOLIC DISEASE · September 1, 2012 Link to item Cite

A canine model of glycogen storage disease type III

Conference MOLECULAR GENETICS AND METABOLISM · March 1, 2012 Link to item Cite

Rapamycin is a potential therapy for glycogen storage disease type III

Conference MOLECULAR GENETICS AND METABOLISM · March 1, 2012 Link to item Cite

Mannose-6-Phosphate receptor expression modulates efficacy from enzyme replacement therapy in Pompe disease

Conference Molecular Genetics and Metabolism · February 2011 Full text Cite

Desensitization through Immunomodulatory Gene Therapy Suppresses the Antibody Response to Enzyme Replacement Therapy in Murine Pompe Disease

Conference MOLECULAR THERAPY · May 1, 2009 Link to item Cite

Muscle-targeted gene therapy in glycogen storage disease type II with adeno-associated virus serotypes 7, 8, and 9

Conference MOLECULAR GENETICS AND METABOLISM · February 1, 2008 Link to item Cite

70 Enhanced response to enzyme replacement therapy in Pompe disease following the induction of immune tolerance

Conference Molecular Genetics and Metabolism · December 2007 Full text Cite

Highly efficacious gene therapy in glycogen storage disease type Ia (GSD-Ia) with a double-stranded AAV vector.

Conference MOLECULAR GENETICS AND METABOLISM · March 1, 2007 Link to item Cite

211. Development of Helper-Dependent Adenovirus (HDAd) Vectors for Gene Therapy in the Mouse Model for Glycogen Storage Disease Type Ia (GSD-Ia)

Conference Molecular Therapy · 2006 Full text Cite

487. Liver-Targeted Gene Therapy in Glycogen Storage Disease Type Ia (GSD-Ia) Requires Widespread, Regulated Glucose-6-phosphatase

Conference Molecular Therapy · 2006 Full text Cite

563. Correction of Glycogen Storage Disease Type II by Systemic Delivery of an AAV2/8 Vector Containing a Muscle-Specific Promoter

Conference Molecular Therapy · 2006 Full text Cite

Efficacy of an adeno-associated virus (AAV) vector administered to glycogen storage disease type Ia (GSD-Ia) mice at mid-infancy.

Conference MOLECULAR GENETICS AND METABOLISM · March 1, 2005 Link to item Cite

339. Sustained, High-Level Expression of Human Acid Alpha-Glucosidase and Correction of Glycogen Storage Disease Type II (GSD II) with an Adeno-Associated Virus 8 (AAV2/8) Vector Containing a Liver-Specific Promoter

Conference Molecular Therapy · May 2004 Full text Cite

Development of adeno-associated virus (AAV) vectors for gene therapy in the mouse model for glycogen storage disease type Ia (GSD-Ia)

Conference MOLECULAR THERAPY · May 1, 2004 Link to item Cite

Correction of glycogen storage disease type II by intramuscular administration of an adeno-associated virus 6 (AAV2/6) vector containing a muscle-specific promoter

Conference MOLECULAR THERAPY · May 1, 2004 Link to item Cite

Correction of glycogen storage disease type II (GSD II) by intramuscular administration of an adeno-associated virus (AAV) vector pseudotyped as AAV6

Conference MOLECULAR THERAPY · May 1, 2003 Link to item Cite

Development of a hybrid adenovirus/adeno-associated virus vector for gene therapy in glycogen storage disease type II

Conference PEDIATRIC RESEARCH · April 1, 2003 Link to item Cite